MENU
RADX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Radiopharm Theranostics (RADX) Ownership - Who owns Radiopharm Theranostics?
Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer... Show more
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
39.5M
P/E Ratio
N/A
Total Cash
36.44M
Projected Growth
N/A
Total Debt
N/A
Revenue
1.68M
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
4.68
Total Debt/Equity
N/A
Revenue/Share
0.29 USD as % of share price
Fundamentals
RADX
Capitalization
39.5M
P/E Ratio
N/A
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
36.4M
Total Cash/Share
4.68
Total Debt
N/A
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.29%
Revenue
1.68M
ROE
N/A
Book Value
53.2M
P/B Ratio
1.13
Cash Flow
N/A
Earnings
-18.66
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
168M
Current Ratio
3.37
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-42.33M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-55.22
Shares Held By Institutions
1.66M
Shares Outstanding - Current
7.78M
Total Liabilities
40.4M
Total Volume MTD
N/A
Value
1
Gain YTD
12.472
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information